Author

Romeo Maciuca 1

1 Genentech Inc., South San Francisco, United States of America

ETROLIZUMAB INDUCTION THERAPY IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: RESULTS FROM THE HICKORY OPEN-LABEL INDUCTION (OLI) TRIAL

Laurent Peyrin-Biroulet, David T. Rubin, Brian G. Feagan, Young S. Oh, Udaysankar Arulmani, Helen Tyrrell, Romeo Maciuca, Sarah Williams, Swati Tole, James Thommes

ETROLIZUMAB TREATMENT DOES NOT MODIFY LEVELS OF VCAM-1 IN ULCERATIVE COLITIS PATIENTS

Franklin Fuh, C Looney, Wei Tew, R Erickson, Romeo Maciuca, Meina Tang, Mary E. Keir, Severine Vermeire, Teresa Ramirez Montagut

ETROLIZUMAB TREATMENT IMPROVES HISTOLOGICAL ACTIVITY AS ASSESSED BY BOTH THE ROBARTS HISTOPATHOLOGY AND NANCY HISTOLOGICAL INDICES

Laurent Peyrin-Biroulet, Brian G. Feagan, Gert De Hertogh, David T. Rubin, Romeo Maciuca, Jacqueline McBride, Udaysankar Arulmani, Alexis Scherl

ETROLIZUMAB TREATMENT MODULATES MADCAM-1 LEVELS IN SERUM IN ULCERATIVE COLITIS PATIENTS

Franklin Fuh, R Erickson, C Schofield, Meina Tang, Romeo Maciuca, Mary E. Keir, Severine Vermeire, Teresa Ramirez Montagut

Item 1 - 4 / 4
1